Related Experiment Videos
New formulation of 5-fluorouracil in microspheres reduces toxicity in mice
A Hagiwara1, C Sakakura, H Tsujimoto
1First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Abstract:
A new dosage formulation of 5-fluorouracil incorporated in microspheres (5-FU-MS) was developed for the treatment of peritoneal carcinomatosis. We studied the acute toxicity and side effects of i.p. 5-FU-MS in mice. The 50% lethal dose value for 5-FU-MS was 535.4 mg/kg of 5-FU, which was 2.22 times that of the aqueous 5-FU solution. Deaths occurred 12-17 days after the administration of 5-FU-MS, but within 11 days after the administration of aqueous 5-FU. Thus, lethal toxicity appeared later with 5-FU-MS than with aqueous 5-FU. There were no differences in pathologic findings on autopsy between mice given the two dosage formulations.
Insights
A novel microsphere formulation of 5-fluorouracil (5-FU-MS) shows reduced acute toxicity compared to aqueous 5-FU. This new formulation for peritoneal carcinomatosis treatment results in delayed mortality in mice.
Area of Science:
- Oncology
- Pharmacology
- Drug Delivery Systems
Background:
- Peritoneal carcinomatosis presents a significant challenge in cancer treatment.
- Conventional 5-fluorouracil (5-FU) administration has limitations.
- Novel drug delivery systems are needed to improve therapeutic outcomes.
Purpose of the Study:
- To develop and evaluate a new microsphere formulation of 5-fluorouracil (5-FU-MS).
- To assess the acute toxicity and side effects of intraperitoneal (i.p.) 5-FU-MS in a murine model.
- To compare the toxicity profile of 5-FU-MS with aqueous 5-FU solution.
Main Methods:
- Development of 5-fluorouracil incorporated in microspheres (5-FU-MS).
- Administration of 5-FU-MS and aqueous 5-FU solution via intraperitoneal injection in mice.
- Acute toxicity assessment, including determination of the 50% lethal dose (LD50).
- Observation of mortality timelines and gross pathological findings post-autopsy.
Main Results:
- The 50% lethal dose (LD50) for 5-FU-MS was 535.4 mg/kg, 2.22 times higher than aqueous 5-FU.
- Mortality in the 5-FU-MS group occurred later (12-17 days) compared to the aqueous 5-FU group (within 11 days).
- No significant differences in pathological findings were observed between the two formulation groups.
Conclusions:
- The novel 5-FU-MS formulation demonstrates a significantly improved safety profile regarding acute toxicity.
- Delayed onset of lethal toxicity suggests a potentially more favorable therapeutic window for 5-FU-MS.
- Further investigation into the efficacy of 5-FU-MS for peritoneal carcinomatosis is warranted.